No other significant differences were found between the different groups of breast cancer patients with respect to TNFα and IL-1β expression in the tumor cells (namely: IDC-no-relapse vs. DCIS; IDC-no-relapse vs. IDC-with-relapse). This evidence concerns the gene IL1B and neoplasm.